BRAIN Biotech AG (XETRA:BNN) — Market Cap & Net Worth
Market Cap & Net Worth: BRAIN Biotech AG (BNN)
BRAIN Biotech AG (XETRA:BNN) has a market capitalization of $51.56 Million (€44.10 Million) as of May 3, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #21764 globally and #1934 in its home market, demonstrating a 7.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BRAIN Biotech AG's stock price €2.76 by its total outstanding shares 21847495 (21.85 Million). Analyse BNN cash flow metrics to see how efficiently the company converts income to cash.
BRAIN Biotech AG Market Cap History: 2016 to 2026
BRAIN Biotech AG's market capitalization history from 2016 to 2026. Data shows change from $446.99 Million to $70.50 Million (-10.90% CAGR).
BRAIN Biotech AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BRAIN Biotech AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.30x
BRAIN Biotech AG's market cap is 1.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $446.99 Million | $22.79 Million | -$14.69 Million | 19.61x | N/A |
| 2017 | $574.70 Million | $24.11 Million | -$9.61 Million | 23.84x | N/A |
| 2018 | $274.83 Million | $27.05 Million | -$8.28 Million | 10.16x | N/A |
| 2019 | $275.85 Million | $38.56 Million | -$10.49 Million | 7.15x | N/A |
| 2020 | $230.90 Million | $38.23 Million | -$9.68 Million | 6.04x | N/A |
| 2021 | $237.54 Million | $38.39 Million | -$4.97 Million | 6.19x | N/A |
| 2022 | $149.17 Million | $49.51 Million | -$6.59 Million | 3.01x | N/A |
| 2023 | $93.48 Million | $55.34 Million | -$8.28 Million | 1.69x | N/A |
| 2024 | $90.67 Million | $54.63 Million | -$11.13 Million | 1.66x | N/A |
| 2025 | $64.37 Million | $49.62 Million | -$11.74 Million | 1.30x | N/A |
Competitor Companies of BNN by Market Capitalization
Companies near BRAIN Biotech AG in the global market cap rankings as of May 3, 2026.
Key companies related to BRAIN Biotech AG by market ranking:
- Linde plc Ordinary Shares (NASDAQ:LIN): Ranked #91 globally with a market cap of $210.18 Billion USD.
- Air Liquide SA (PA:AI): Ranked #222 globally with a market cap of $108.00 Billion USD ( €92.38 Billion EUR).
- AIR LIQUIDE ADR 1/5/EO 11 (F:AILA): Ranked #232 globally with a market cap of $103.86 Billion USD ( €88.84 Billion EUR).
- Sherwin-Williams Co (NYSE:SHW): Ranked #334 globally with a market cap of $78.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Linde plc Ordinary Shares | NASDAQ:LIN | $210.18 Billion | $507.92 |
| #222 | Air Liquide SA | PA:AI | $108.00 Billion | €183.08 |
| #232 | AIR LIQUIDE ADR 1/5/EO 11 | F:AILA | $103.86 Billion | €36.60 |
| #334 | Sherwin-Williams Co | NYSE:SHW | $78.83 Billion | $318.00 |
BRAIN Biotech AG Historical Marketcap From 2016 to 2026
Between 2016 and today, BRAIN Biotech AG's market cap moved from $446.99 Million to $ 70.50 Million, with a yearly change of -10.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €70.50 Million | +9.52% |
| 2025 | €64.37 Million | -29.01% |
| 2024 | €90.67 Million | -3.01% |
| 2023 | €93.48 Million | -37.33% |
| 2022 | €149.17 Million | -37.20% |
| 2021 | €237.54 Million | +2.88% |
| 2020 | €230.90 Million | -16.30% |
| 2019 | €275.85 Million | +0.37% |
| 2018 | €274.83 Million | -52.18% |
| 2017 | €574.70 Million | +28.57% |
| 2016 | €446.99 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of BRAIN Biotech AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $51.56 Million USD |
| MoneyControl | $51.56 Million USD |
| MarketWatch | $51.56 Million USD |
| marketcap.company | $51.56 Million USD |
| Reuters | $51.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more